Bristol-Myers Squibb

Associate Scientist, Material Science & Engineering

Posted on: 5 Feb 2021

New Brunswick, NJ

Job Description

At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.

As an Associate Scientist in the Drug Product Development - Materials Science and Engineering Group, the main responsibilities will be tailoring the API material characteristics to balance both drug substance processability and drug product performance. Activities will include form screening, crystallization process development and particle engineering approaches to deliver the desired material properties and ultimately a robust crystallization, isolation and drying protocol for pilot and commercial scale manufacturing. The candidate is expected to apply physical chemistry and engineering principles to achieve these goals.

It is expected that the candidate will work with a broad range of materials, including crystalline and non-crystalline APIs including small molecules, peptides, oligonucelotides as well as drug product intermediates that will be used in the design of robust oral and injectable drug product formulations. Experience in laboratory experimentation is expected and expertise in solid state characterization techniques such as XRD, BET, TGA, and DSC is desired. In addition, an understanding of PAT techniques (Raman, Lasentec, ATR-FTIR, NIR) and their application to crystallization process development is desired.

Requirements: B.S. or M.S. in chemical engineering or related field with 0 to 4 years of pharmaceutical/chemical industry. Excellent problem solving skills with a strong background in process development is required. Experience in process scale up, particularly in crystallization and drying is desired. Experience with complex molecule crystallization, particle engineering and/or other novel isolation techniques for millamolecules, oligonucleotide, peptides and proteins is highly desirable.

The individual will effectively interface and collaborate across drug substance, drug product and analytical development teams. The individual must have demonstrated ability to identify and solve problems. Outstanding oral and written communication skills with the ability to provide technical input and scientific leadership are required. This position requires employees to work safely at laboratory and pilot plant scale with chemical agents which may pose health or safety hazards if improperly handled.

Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.

Bristol-Myers Squibb

New York, New York

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd.

The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

  • Industry
    Biopharmaceuticals
  • No. of Employees
    23, 300
  • Jobs Posted
    1641

Similar Jobs